Aprea Therapeutics Inc (APRE) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Aprea Therapeutics Inc   (NASDAQ: APRE)


Aprea Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Aprea Therapeutics Inc's ROI in the second quarter of 2026?
Aprea Therapeutics Inc recorded a cumulative net loss of $-12 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -46.3%.

Within the Healthcare sector 270 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3159 to 3773.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 41.99 % -7.24 % -44.73 % -35.86 % -22.78 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 39 42 13 12 14
Return On Investment (TTM) -46.3 % -58.84 % -90.3 % -82.44 % -73.99 %
APRE's Overall Ranking # 3773 # 3159 # 3300 # 3776 # 3459
Seq. Investment Change TTM 30.83 % 45.61 % -11.78 % -15.52 % -14.53 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -12 -12 -13 -13 -14

APRE Company Profile >> Back to APRE Roi Comparisons >> See Annual APRE Return On Investment



Return On Investment APRE's Ranking
Within: No.
Industry # 97
Sector # 271
Overall # 3773

Return On Investment Statistics
High Average Low
-46.3 %
-104.85 %
-371.83 %
(Jun 30 2026)   (Mar 31 2023)



  News about Aprea Therapeutics Inc Return on Investment ROI

Aprea Therapeutics Announces Engagement of Dr. Philippe Pultar as Senior Medical Advisor to Lead Development of WEE1 Inhibitor APR-1051 Amid New Clinical Trial Initiatives,

October 9, 2024

Aprea Therapeutics Expands Expertise with Appointment of Philippe Pultar, MD, to Lead WEE1 Clinical Development Amid New Trial InitiativesAprea Therapeutics Inc. a clinical-stage biopharmaceutical company specializing in precision oncology through the innovative concept of synthetic lethality, has made significant strides in its quest to advance cancer treatment options. On October 9, 2024, the company announced the engagement of Dr. Philippe Pultar as its Senior Medical Advisor, a strategic decision aimed at enhancing the development and clinical advancement of its promising WEE1 inhibitor, APR-1051. Strengthening Leadership in Clinical DevelopmentDr. Pultar brings a wealth of experience to Aprea Therapeutics, having an established track record in oncology and drug development. His expertise will be instrumental as the company seeks to bolster its pipeline, particularly with the WEE1 inhibitor, which has the potential to redefine treatment approaches for patients with specific cancer types.





Financial Statements
Aprea Therapeutics Inc's II. Quarter Investments $ 39 Millions APRE's Balance sheet
Aprea Therapeutics Inc's II. Quarter Income $ -4 Millions Quarterly APRE's Income Statement
APRE's Income by Division See APRE's Income by Division


APRE Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 13 21 18 27 50
Y / Y Investment Growth -36.13 % 12.89 % -32.24 % -45.55 % -36.1 %
Net Income in Millions -13 -13 -14 -113 -37
Y / Y Net Income Growth - - - - -
Annual Return On Investment -95.68 % -62.85 % -78.22 % -417.97 % -74.99 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
APRE's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for APRE's Competitors
Subscribers only: Roi for Aprea Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for APRE's Customers

Other Ratios
APRE's Roa APRE's Inventory Turnover Ratio APRE's Growth Rates APRE's Dividend Statistics
APRE's Profitability Ratios APRE's Asset Turnover Ratio APRE's Dividend Growth
APRE's Roe APRE's Valuation Ratios APRE's Financial Strength Ratios APRE's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-08T16:33:55+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.